Poukisa pasyan lesemi yo oblije fè twou zo a repete?

Nan travay klinik, kèk pasyan lesemi yo souvan anwiye ak aspirasyon mwèl zo souvan, ak fanmi yo souvan difisil pou konprann.

An reyalite, li trè nesesè yo repete fè egzamen mwèl zo pou pasyan lesemi, rezon ki fè yo se ke nan adisyon a dyagnostik klè, li pi enpòtan yo obsève efè a guérison apre tretman an. Pou pasyan lesemi ki pa te remèt, anjeneral 10 a 14 jou apre chimyoterapi, byopsi zo obligatwa pou konprann repons tretman dènye chimyoterapi a, ede doktè detèmine efè chimyoterapi sa a, epi bay plis plan tretman ak chwa dwòg. an akó ak.

After combined chemotherapy, the percentage of leukemia cells in the bone marrow decreased by less than 40 percent compared with that before chemotherapy, which indicates that the patient may not be sensitive to the chemotherapy drugs used. other medicines. In addition, bone marrow aspirate can also help doctors to judge the prognosis. If the percentage of leukemia cells in the bone marrow of a patient has not decreased significantly despite multiple regimens of chemotherapy, or has decreased for a while, but has risen to the level before treatment in a short period of time, it indicates that this is the case. The leukemia cells in the patient have primary drug resistance, which is difficult to treat and has a poor prognosis. Conversely, if the patient has sustained complete remission on every repeat bone marrow examination, the patient's prognosis is good. For patients with persistent remission, regular bone marrow examination can monitor the changes of the condition and prevent problems before they occur. Early detection, early treatment and early control of leukemia may occur at the beginning of relapse, so as to prolong the survival period and improve the curative effect.